Last updated: March 3, 2026
What is the Drug Associated with NDC 82009-0074?
NDC 82009-0074 corresponds to Methylprednisolone Sodium Succinate, Injection, USP. It is used as an anti-inflammatory and immunosuppressant in various indications, such as allergy, asthma, and autoimmune disorders. It is supplied as a sterile, parenteral solution.
Market Size and Key Drivers
Current Market Scope
- Global corticosteroid injectables, including methylprednisolone, are valued at approximately $1.8 billion in 2022.
- The segment exhibits a compound annual growth rate (CAGR) of roughly 3.2% through 2027, driven mainly by increasing prevalence of autoimmune diseases, allergy conditions, and respiratory disorders.
Major Market Segments
| Segment |
Contribution |
Notes |
| Hospitals |
55% |
High utilization for acute and emergency care. |
| Specialty clinics |
30% |
Used extensively for autoimmune disorders. |
| Retail pharmacies |
15% |
Less common, mostly for outpatient care. |
Key Growth Drivers
- Rising incidence of rheumatoid arthritis, multiple sclerosis, and asthma.
- Expansion of outpatient infusion services.
- Cost-efficient generic options increasing accessibility.
Competitive Landscape
- Leading manufacturers: Pfizer, Sandoz, and Mylan distribute methylprednisolone injectable formulations.
- Entry of biosimilars or biosimilar-like injectables poses potential competitive threats.
Pricing Trends and Projections
Current Price Benchmarks
| Product Type |
Price per Dose (USD) |
Unauthorized vs. Brand |
Notes |
| Branded methylprednisolone |
$10 - $15 |
Generally higher |
Pfizer’s Solu-Medrol as benchmark. |
| Generic methylprednisolone |
$3 - $7 |
Lower |
Dominates market share. |
Factors Influencing Prices
- Regulatory changes: FDA approval and generic patent expirations impact pricing.
- Supply chain stability: Disruptions and raw material costs influence prices.
- Healthcare policies: Reimbursement policies and inflation impact profit margins.
Price Projection (2023–2028)
| Year |
Estimated Price per Dose (USD) |
Comments |
| 2023 |
$3.50 - $7.50 |
Stability expected; potential small decreases as generics proliferate. |
| 2024 |
$3.30 - $7.00 |
Slight decline anticipated with continued generic competition. |
| 2025 |
$3.25 - $6.50 |
Market saturation with generics; further price pressure. |
| 2026 |
$3.20 - $6.00 |
Stabilization at lower price bounds. |
| 2027 |
$3.00 - $5.75 |
Marginal decline as biosimilar-like injectables emerge. |
| 2028 |
$2.80 - $5.50 |
Market approaches price floor driven by cost competitiveness. |
Impact of Biosimilar and Generic Entry
The increased availability of biosimilar or biosimilar-like injectables may further reduce prices by approximately 10-15% over the next 3-5 years.
Regulatory & Policy Outlook
- Patent expirations for key formulations occurred circa 2015-2017.
- FDA approval pathways for biosimilars are evolving, influencing future competition.
- Recent legislation (e.g., Inflation Reduction Act) promotes generic drug affordability, expected to lower prices.
Market Entry & Investment Considerations
- Entry barriers for new competitors include regulatory approval and manufacturing complexity.
- Price erosion may limit profit margins on new formulations.
- Investment focus should target jurisdictions with high disease prevalence, such as North America and Europe.
Key Takeaways
- NDC 82009-0074 corresponds to methylprednisolone sodium succinate injectable.
- The market is mature with significant generic penetration, maintaining price declines.
- Prices are projected to decline gradually, influenced by ongoing generic competition and biosimilar entries.
- Growth driven by rising autoimmune and respiratory disease prevalence, and healthcare delivery shifts.
- Investors should monitor biosimilar developments and policy changes impacting pricing dynamics.
FAQs
1. What factors most influence methylprednisolone injectable prices?
Patent expirations, generic competition, biosimilar emergence, supply chain costs, and healthcare policy reforms.
2. How does biosimilar competition affect market prices?
It typically decreases prices by introducing more affordable options, with an estimated 10-15% reduction over current levels within five years.
3. Which regions have the highest market growth potential?
North America and Europe, due to higher disease prevalence and mature healthcare infrastructure.
4. Are there significant differences between brand-name and generic methylprednisolone?
Yes. Brand-name products like Solu-Medrol tend to be priced higher ($10-$15 per dose), while generics are significantly cheaper ($3-$7).
5. What regulatory risks could impact the market?
Delays in biosimilar approvals, patent litigation, or changes in reimbursement policies could alter competitive dynamics and prices.
References
- IQVIA. (2022). Global corticosteroid injectables market analysis.
- U.S. Food and Drug Administration. (2021). Biosimilar pathway and approvals.
- EvaluatePharma. (2022). Pharmaceutical pricing and market trends.
- Centers for Disease Control and Prevention. (2022). Autoimmune disease prevalence.
- Statista. (2022). Global healthcare market projections.
